The Leukemia & Lymphoma Society Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:The Leukemia & Lymphoma Society Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013302
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
The Leukemia & Lymphoma Society Inc (LLS) is a health organization that offers funding research, finding cures and access to treatments for blood cancer patients. The organization’s services include patient support, health education, policy advocacy, funds raising and medical research funding. It offers treatments for various diseases, which include leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and myeloma. LLS offer diagnosis and treatement of blood cancers by funding academic research, therapy acceleration program and other specialized initiatives. The organization partners with pharmaceutical and biotechnology companies, patients support services and advocates working for blood cancer patients. It has operations in the US and Canada. LLS is headquartered in Rye Brook, New York, the US.

The Leukemia & Lymphoma Society Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OncoPep Raises USD7 Million in Series B Venture Financing 11
Partnerships 12
NexImmune and Leukemia & Lymphoma Society Enter into Partnership 12
Selvita Enters into Agreement with Leukemia & Lymphoma Society 13
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 14
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 15
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 16
Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 17
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 18
Curis Enters Into Co-Development Agreement With The Leukemia & Lymphoma Society 19
Leukemia & Lymphoma Society Enters Into An Agreement With EpiZyme 21
Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 22
Equity Offering 23
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 23
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 24
The Leukemia & Lymphoma Society Inc – Key Competitors 25
The Leukemia & Lymphoma Society Inc – Key Employees 26
The Leukemia & Lymphoma Society Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Corporate Communications 29
Mar 16, 2017: LLS APPOINTS DR. GWEN NICHOLS, CHIEF MEDICAL OFFICER 29
Government and Public Interest 30
Nov 21, 2017: The Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy research 30
Nov 16, 2016: World Leading Cancer Organization Invests $40.3 Million in New Research to Find Cures 31
Product News 32
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 32
Other Significant Developments 34
Nov 20, 2017: LLS Funds $46 Million in New Research to Find Cures 34
Nov 16, 2016: LLS Invests $40.3 Million in New Research to Find Cures 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Key Facts 2
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Leukemia & Lymphoma Society Inc, Deals By Therapy Area, 2011 to YTD 2017 8
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
OncoPep Raises USD7 Million in Series B Venture Financing 11
NexImmune and Leukemia & Lymphoma Society Enter into Partnership 12
Selvita Enters into Agreement with Leukemia & Lymphoma Society 13
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 14
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 15
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 16
Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 17
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 18
Curis Enters Into Co-Development Agreement With The Leukemia & Lymphoma Society 19
Leukemia & Lymphoma Society Enters Into An Agreement With EpiZyme 21
Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 22
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 23
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 24
The Leukemia & Lymphoma Society Inc, Key Competitors 25
The Leukemia & Lymphoma Society Inc, Key Employees 26

★海外企業調査レポート[The Leukemia & Lymphoma Society Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Meredith Corporation (MDP):企業の財務・戦略的SWOT分析
    Meredith Corporation (MDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • China Pacific Insurance (Group) Co Ltd:企業のM&A・事業提携・投資動向
    China Pacific Insurance (Group) Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Pacific Insurance (Group) Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Latvenergo AS:企業の戦略的SWOT分析
    Latvenergo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • athenahealth Inc (ATHN):医療機器:M&Aディール及び事業提携情報
    Summary athenahealth Inc (athenahealth) is a provider of cloud-based business services and mobile applications for medical groups and health system. The company offers network-enabled services for revenue cycle management and medical billing, electronic health records (EHR), patient engagement, popu …
  • Theratechnologies Inc (TH):企業の財務・戦略的SWOT分析
    Theratechnologies Inc (TH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Encision Inc (ECIA):医療機器:M&Aディール及び事業提携情報
    Summary Encision Inc (Encision) is a medical device company that manufactures and markets surgical instruments. The company provides laparoscopic monopolar surgical instruments. Its product portfolio includes AEM burn protection systems, AEM instrumentation, cord adapter, inhibit adapter extension, …
  • Actinium Pharmaceuticals Inc (ATNM):企業の財務・戦略的SWOT分析
    Summary Actinium Pharmaceuticals Inc (Actinium), formerly Cactus Ventures Inc, is a biopharmaceutical company. It develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company's pipeline products include Iomab- …
  • Lincoln National Corporation:戦略・SWOT・企業財務分析
    Lincoln National Corporation - Strategy, SWOT and Corporate Finance Report Summary Lincoln National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • TriVascular Inc:医療機器:M&Aディール及び事業提携情報
    Summary TriVascular Inc (TriVascular), a subsidiary of Endologix Inc is a medical device company that researches, designs and manufactures technologies to provide optimal solutions for endovascular aortic repair. The company’s product comprise endovascular grafts and self-expanding stent grafts; ova …
  • Petroleo Brasileiro SA (PETR4):企業の財務・戦略的SWOT分析
    Petroleo Brasileiro SA (PETR4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Trendlines Group Ltd (42T):製薬・医療:M&Aディール及び事業提携情報
    Summary The Trendlines Group Ltd (Trendlines) is a commercialization company that invents, discovers, invests, and incubates medical and agricultural technologies. The company offers business incubation, partner and channel development, market strategies, business plans, research and development and …
  • Piramal Enterprises Ltd (PEL):企業の財務・戦略的SWOT分析
    Piramal Enterprises Ltd (PEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Tokyo Electron Limited:企業の戦略・SWOT・財務情報
    Tokyo Electron Limited - Strategy, SWOT and Corporate Finance Report Summary Tokyo Electron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Great Eastern Holdings Limited (G07):企業の財務・戦略的SWOT分析
    Great Eastern Holdings Limited (G07) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbioti …
  • Neuralstem Inc (CUR):企業の財務・戦略的SWOT分析
    Summary Neuralstem Inc (Neuralstem) is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peri …
  • Yamato Holdings Co Ltd (9064):企業の財務・戦略的SWOT分析
    Yamato Holdings Co Ltd (9064) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Avitide Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avitide Inc (Avitide) strives to discover, manufacture and commercialize molecule-specific affinity purification solutions for biopharmaceutical industry. It offers affinity purification resins for developing bio-molecules including enzymes, non-antibody therapeutics, bispecific antibodies, …
  • PT Telekomunikasi Indonesia, Tbk:企業の戦略・SWOT・財務情報
    PT Telekomunikasi Indonesia, Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Telekomunikasi Indonesia, Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • The Advisory Board Company:企業の戦略的SWOT分析
    The Advisory Board Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆